The stock of Takeda Pharmaceutical Co ADR (TAK) has gone down by -5.06% for the week, with a 1.49% rise in the past month and a 4.85% rise in the past quarter. The volatility ratio for the week is 1.68%, and the volatility levels for the past 30 days are 1.61% for TAK. The simple moving average for the past 20 days is -4.06% for TAK’s stock, with a 0.91% simple moving average for the past 200 days.
Is It Worth Investing in Takeda Pharmaceutical Co ADR (NYSE: TAK) Right Now?
Takeda Pharmaceutical Co ADR (NYSE: TAK) has a price-to-earnings ratio that is above its average at 33.56x. The stock has a 36-month beta value of 0.27. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TAK is 3.17B, and at present, short sellers hold a 0.16% of that float. On May 09, 2025, the average trading volume of TAK was 1.89M shares.
TAK) stock’s latest price update
Takeda Pharmaceutical Co ADR (NYSE: TAK)’s stock price has plunge by -5.25relation to previous closing price of 15.06. Nevertheless, the company has seen a -5.06% plunge in its stock price over the last five trading sessions. benzinga.com reported 2025-05-08 that Takeda Pharmaceutical Company Limited TAK reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year.
Analysts’ Opinion of TAK
BofA Securities, on the other hand, stated in their research note that they expect to see TAK reach a price target of $20. The rating they have provided for TAK stocks is “Buy” according to the report published on March 16th, 2023.
Cowen gave a rating of “Outperform” to TAK, setting the target price at $24 in the report published on July 19th of the previous year.
TAK Trading at -4.17% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.49% of loss for the given period.
Volatility was left at 1.61%, however, over the last 30 days, the volatility rate increased by 1.68%, as shares sank -0.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.49% lower at present.
During the last 5 trading sessions, TAK fell by -5.06%, which changed the moving average for the period of 200-days by +5.63% in comparison to the 20-day moving average, which settled at $14.87. In addition, Takeda Pharmaceutical Co ADR saw 7.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TAK starting from Giles Richard Platford, who proposed sale 19,073 shares at the price of $14.94 back on Aug 23 ’24. After this action, Giles Richard Platford now owns shares of Takeda Pharmaceutical Co ADR, valued at $284,951 using the latest closing price.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.55 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.05. The total capital return value is set at 0.04. Equity return is now at value 2.87, with 1.38 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 2.28.
Currently, EBITDA for the company is 874.6 billion with net debt to EBITDA at 3.63. When we switch over and look at the enterprise to sales, we see a ratio of 2.42. The receivables turnover for the company is 6.23for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.
Conclusion
To sum up, Takeda Pharmaceutical Co ADR (TAK) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
